Intensive Weight Loss Intervention Versus Bariatric Surgery for Adults With Severe and Complex Obesity: the LightBAR Randomised Trial
Launched by CARSTEN DIRKSEN · Mar 6, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The LightBAR trial is studying two different ways to help adults with severe obesity lose weight: a non-surgical program that includes meal replacements, behavioral support, and weight-loss medications, versus bariatric surgery, which is a surgical option for weight loss. The goal is to understand which method works better and what the benefits and risks are for people who qualify for bariatric surgery. By comparing these two approaches, the results may help shape future treatments for individuals struggling with obesity.
To participate in this trial, you need to be between 18 and 60 years old and eligible for bariatric surgery based on specific health criteria. This may include having a high body mass index (BMI) and related health issues like diabetes or high blood pressure. Participants will be invited to join the study and can expect to either follow the intensive weight loss program or undergo surgery, with regular support and monitoring throughout the process. It's important to know that certain health conditions or previous surgeries may prevent someone from taking part in the trial, so a thorough screening will be done to ensure safety and suitability.
Gender
ALL
Eligibility criteria
- • Please note that participants need to be invited in order to take part in the trial.
- Inclusion Criteria:
- • Aged 18 to 60 years (inclusive) at time of screening.
- * Eligible for and willing to undergo bariatric surgery, i.e., fulfilment of criteria for bariatric surgery from the respective national health authorities:
- • DK: BMI ≥ 35 kg/m2 with one or more of the following: T2D, severe hypertension, sleep apnoea requiring treatment, symptomatic arthrosis in lower extremities, female infertility related to overweight, or BMI\>40 kg/m2 with other strong medical reasons for weight loss (28). Prior to surgery, an 8% weight loss is required as well as smoking cessation.
- • UK: BMI of 35 kg/m2 to 40 kg/m2 and other significant disease (e.g., type 2 diabetes or high blood pressure), or BMI ≥40 kg/m2. Has been or is willing to receive intensive management in a specialist tier 3 obesity service (29).
- • Fit for anaesthesia and surgery.
- • Informed consent.
- Exclusion Criteria:
- • Prior bariatric or hiatal surgery, not including intragastric balloons or duodenal-jejunal bypass sleeve (Endobarrier™ or similar) if the device has been removed \>1 year before screening.
- • Use of any WLM (including liraglutide and semaglutide for diabetes) within last 3 months.
- • Conditions that contraindicate or complicate total diet replacement (including type 1 diabetes or other diabetes requiring basal bolus insulin therapy or insulin pump therapy (for Denmark) and any diabetes requiring insulin therapy (for UK), phenylketonuria, or other conditions requiring strict adherence to special diets).
- • Conditions that contraindicate or complicate treatment with GLP-1 receptor analogues (including history of pancreatitis or known allergies).
- • Conditions that contraindicate or complicate bariatric surgery (GI motility disorders, large abdominal wall hernia, large hiatus hernia (\>5cm), Crohn's disease, liver cirrhosis, or other conditions preventing laparoscopic bariatric surgery e.g. multiple previous abdominal surgery).
- • Conditions that contraindicate or complicate study adherence and bariatric surgery (mental disorder, unstable psychiatric disease, recent history of alcohol/medication abuse, cancer treatment within 5 years).
- • Pregnant or planning pregnancy in the next two years or currently breast feeding.
- • Not achieving a 5% weight loss within 12 weeks prior to randomisation.
- • People taking part in other research involving multidisciplinary obesity treatment that would compromise their participation in this trial.
- • Another member of the household enrolled in the trial.
- • Diagnosis of or treatment for severe eating disorder within the last 6 months.
About Carsten Dirksen
Carsten Dirksen is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a focus on enhancing patient outcomes, Dirksen oversees a range of clinical studies aimed at evaluating novel therapeutics and interventions across various therapeutic areas. His expertise in trial design, regulatory compliance, and data integrity ensures that each study is conducted with the highest standards of scientific rigor and ethical responsibility. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, Carsten Dirksen plays a pivotal role in translating scientific discoveries into effective treatments for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southampton, , United Kingdom
Truro, Cornwall, United Kingdom
Viborg, , Denmark
Aarhus, , Denmark
Esbjerg, , Denmark
Hvidovre, , Denmark
Køge, , Denmark
Bristol, , United Kingdom
Taunton, , United Kingdom
Cosham, Portsmouth, United Kingdom
Chichester, Sussex, United Kingdom
Patients applied
Trial Officials
Carsten Dirksen, Ass Professor
Study Chair
Department of Medicine, Copenhagen University Hospital - Amager and Hvidovre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported